Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
ISOTRETINOIN CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 4 | First Supplement to USP36–NF31 | 6000 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 13 of System suitability: Add section heads before "Calculate the percentage....": Analysis Samples: Standard solution and Sample solution |
CYCLOBENZAPRINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP36–NF31 | 6585 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 2 of USP Cyclobenzaprine Related Compound A RS: Change 5-[3-(Dimethylamino)propyl]-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-ol. to: 5-[3-(Dimethylamino)propyl]-5H-dibenzo[a,d]-cyclohepten-5-ol. |
TRAMADOL HYDROCHLORIDE | ASSAY/Procedure | Second Supplement to USP36–NF31 | 6715 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 2 of System suitability solution: Change USP Tramadol Hydrochloride Related Compound A RS to: USP Tramadol Related Compound A RS |
BOSWELLIA SERRATA EXTRACT | COMPOSITION/Content of Keto-Derivatives of β-Boswellic Acids/System suitability/Suitability requirements | USP36–NF31 | 1367 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 1 of Tailing factor: Change 11-keto-β-boswellic acid peak to: 3-acetyl-11-keto-β-boswellic acid peak |
CARVEDILOL | IMPURITIES/Organic Impurities, Procedure 3: Carvedilol Related Compound F | USP36–NF31 | 2822 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 2 of Sample solution:
Change Use about 1.9 mL of Diluent per mg of the Carvedilol, and sonicate briefly to facilitate dissolution. to: Initially add Diluent to fill about 80% of the total volume. Sonicate briefly to facilitate dissolution. Cool, and dilute with… Read More |
LEVALBUTEROL INHALATION SOLUTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP36–NF31 | 4080 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 35:
Delete USP Levalbuterol Related Compound H RS 4-[2-(tert-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol. C14H23NO3 253.34 |
RISPERIDONE ORALLY DISINTEGRATING TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP36–NF31 | 5067 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 2 of USP Risperidone Related Compounds Mixture RS: Change Contains a 98.9/0.5/0.3/0.3 (area %) mixture of the following four compounds: Risperidone (98.9%) Risperidone cis-N-oxide (0.5%): cis-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9… Read More |
VALERIAN TINCTURE | STRENGTH/Content of Valerenic Acids | Second Supplement to USP36–NF31 | 6352 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 1 of Acceptance criteria: Change 90.0%–120.0% to: NLT 0.015% of valerenic acids, calculated as the sum of hydroxyvalerenic acid, acetoxyvalerenic acid, and valerenic acid |
PARICALCITOL INJECTION | IMPURITIES/Organic Impurities/Chromatographic system/Columns | Second Supplement to USP36–NF31 | 6678 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 1 of Guard: Change 4.6-mm × 7.5-cm to: 4.6-mm × 7.5-mm |
FERRIC AMMONIUM CITRATE | Mercury | USP36–NF31 | 2469 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 5 of Standard solutions: Change 2.5, 5.0, 10.0, and 35.0 µg to: 2.5, 5.0, 10.0, and 35.0 ng |
GRANISETRON HYDROCHLORIDE INJECTION | Assay | USP36–NF31 | 3772 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 10 of Procedure: Change 100(312.41 / 348.87)(C/L)(rU / rS) to: 100(312.41 / 348.87)(C/CU)(rU / rS) AND Line of 14 of Procedure: Change L is… Read More |
ETHYL OLEATE | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 2006 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Change: and to: or |
OXYMETAZOLINE HYDROCHLORIDE OPHTHALMIC SOLUTION | Identification | USP36–NF31 | 4652 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change A volume of Ophthalmic Solution, equivalent to about 2.5 mg of oxymetazoline hydrochloride, responds to the Identification test under Oxymetazoline Hydrochloride Nasal Solution. to: Place a volume of Ophthalmic Solution, equivalent to about 2.5 mg of… Read More |
LINOLEOYL POLYOXYLGLYCERIDES | IMPURITIES/Limit of Free Glycerol | USP36–NF31 | 2068 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Mode in Titrimetric system: Change Direct titration to: Residual titration AND Line 10 of Analysis: Change (VS − VB) to: (VB − VS) AND Line 11 of Analysis:… Read More |
RIVASTIGMINE TARTRATE | CHEMICAL INFORMATION | USP36–NF31 | 5073 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change 398.41 to: 400.42 |
POLYSORBATE 80 | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 2163 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |
BACLOFEN | ASSAY/Procedure/Chromatographic system | First Supplement to USP36–NF31 | 5951 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Column: Change 250-cm to: 25.0-cm |
SORBITAN MONOSTEARATE | IDENTIFICATION/A. | USP36–NF31 | 2214 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 200–215 to: 200–215 on 1-g sample |
FILGRASTIM | ASSAY/Potency | Second Supplement to USP36–NF31 | 6606 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 7 of Preparation of cells for analysis: Change Column 1 is filled with 50 L of Medium B. to: Column 1 is filled with 50 µL of Medium B. |
BUTABARBITAL SODIUM TABLETS | Identification, Infrared Absorption <197K> | USP36–NF31 | 2716 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 5 of Test specimen: Change Proceed as directed for Column Partition Chromatography under Chromatography <621>, packing the chromatographic tube as follows. to: Pack a chromatographic tube as follows. |
DILUTED ALCOHOL | ADDITIONAL REQUIREMENTS | USP36–NF31 | 1874 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Delete USP Reference Standards <11> section |
DROSPIRENONE | IMPURITIES/Organic Impurities/Procedure 2 | USP36–NF31 | 3349 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | In footnote b of Table 4: Change 5β,17β-Dihydroxy-6β,7β:15β,16β-dimethylene-17α-pregnan-21-carboxylic acid, γ-lactone. to: 5β,17-Dihydroxy-6β,7β:15β,16β-dimethylene-3-oxo-17α-pregnan-21-carboxylic acid, γ-lactone. |
CETYL ALCOHOL | SPECIFIC TESTS/Fats and Fixed Oils, Hydroxyl Value <401> | USP36–NF31 | 1956 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Mode in Titrimetric system: Change Direct titration to: Residual titration AND Line 9 of Analysis: Change Result = [(VS − VB) × F]/W to: Result = [(VB… Read More |
METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 2/System suitability | USP36–NF31 | 4327 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Capacity factor: Change NMT 2 to: NLT 2 |
HYDROXYETHYL CELLULOSE | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 2038 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |
RIFAMPIN, ISONIAZID, PYRAZINAMIDE, AND ETHAMBUTOL HYDROCHLORIDE TABLETS | Assay for rifampin, isoniazid, and pyrazinamide | USP36–NF31 | 5047 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 12 of Procedure: Change the Standard preparation and the Assay preparation, respectively. to: the Assay preparation and the Standard preparation, respectively. |
POLYOXYL 10 OLEYL ETHER | SPECIFIC TESTS/Average Polymer Length | USP36–NF31 | 2150 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 9 of Analysis: Change Result = [(31 A2/A1 − 3)]/4 to: Result = [(31 × A2/A1) − 3]/4 |
COMPOUND UNDECYLENIC ACID OINTMENT | Assay for zinc undecylenate | USP36–NF31 | 5516 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 15 of Procedure: Change 431.94 is the molecular weight of zinc undecylenate; to: Mr is the molecular weight of zinc undecylenate, 431.94; AND Line 16 of Procedure: Change 65.39 is the atomic weight of zinc; to: Ar… Read More |
SORBITAN MONOOLEATE | IDENTIFICATION/A. | USP36–NF31 | 2213 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 192–204 to: 192–204 on 1-g sample |
QUININE SULFATE TABLETS | ASSAY/Procedure | First Supplement to USP36–NF31 | 6046 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 4 of Analysis: Change dihydroquinone sulfate to: dihydroquinine sulfate |
STEAROYL POLYOXYLGLYCERIDES | IMPURITIES/Limit of Free Glycerol | USP36–NF31 | 2250 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 11 of Analysis: Change (VS − VB) to: (VB − VS) AND Line 12 of Analysis: Change VS = Titrant volume consumed by the Sample… Read More |
<232> ELEMENTAL IMPURITIES—LIMITS | ANALYTICAL TESTING | USP36–NF31 | 151 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change If, by validated processes and supply-chain control, to: If, by process monitoring and supply-chain control, |
CARISOPRODOL, ASPIRIN, AND CODEINE PHOSPHATE TABLETS | USP Reference standards <11> | USP36–NF31 | 2813 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of USP Codeine N-Oxide RS: Change C18H21O4 to: C18H21NO4 |
CAPRYLOCAPROYL POLYOXYLGLYCERIDES | IMPURITIES/Limit of Free Glycerol | USP36–NF31 | 1922 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Mode in Titrimetric system: Change Direct titration to: Residual titration AND Line 10 of Analysis: Change (VT − VB) to: (VB − VS) AND… Read More |
FERUMOXSIL ORAL SUSPENSION | Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 3572 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |
FERROSOFERRIC OXIDE | IMPURITIES | USP36–NF31 | 2018 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample solution C in Limit of Lead (Pb): Change Sample solution to: Sample stock solution AND Line 1 of Sample solution D in Limit of Lead (Pb): Change Sample solution to: Sample stock solution AND Line… Read More |
POLYVINYL ALCOHOL | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911>, Rotational Rheometer Methods <912>, and Rolling Ball Viscometer Method <913> | USP36–NF31 | 4830 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change and to: or |
OLEOYL POLYOXYLGLYCERIDES | IMPURITIES/Limit of Free Glycerol | USP36–NF31 | 2112 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Mode in Titrimetric system: Change Direct titration to: Residual titration AND Line 10 of Analysis: Change (VS − VB) to: (VB − VS) AND Line 11 of Analysis:… Read More |
SALICYLIC ACID | USP Reference standards <11> | USP36–NF31 | 5098 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 3 of USP Salicylic Acid Related Compound A RS: Change [CAS-99-96-7]. to: [99-96-7]. AND Line 3 of USP Salicylic Acid Related Compound B RS: Change C8H6O4 to: C8H6O5 |
POTASSIUM METAPHOSPHATE | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 2172 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |
ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities, Procedure 2 | First Supplement to USP36–NF31 | 5996 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 3: Change the section head Isosorbide mononitrate related compound A stock solution: to: Isosorbide mononitrate related compound A standard stock solution: AND Line 7: Change the section head Isosorbide dinitrate stock solution: to: Isosorbide… Read More |
SORBITAN SESQUIOLEATE | IDENTIFICATION/A. | USP36–NF31 | 2215 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 192–204 to: 192–204 on 1-g sample |
PANCURONIUM BROMIDE INJECTION | IMPURITIES/Organic Impurities | Second Supplement to USP36–NF31 | 6677 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Footnote a of Table 1: Change Piperidinium, 1-[(2,3,5,16,17)-17-acetyloxy-3-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl bromide. to: Piperidinium, 1-[(2,3,5,16,17)-17-acetyloxy-3-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl. |
CAFFEINE CITRATE INJECTION | Assay | USP36–NF31 | 2732 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 3 of Chromatographic system: Change 150-cm column to: 15-cm column |
BEHENOYL POLYOXYLGLYCERIDES | IMPURITIES/Limit of Free Glycerol/Titrimetric system | USP36–NF31 | 1892 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Mode: Change Direct titration to: Residual titration |
ESOMEPRAZOLE MAGNESIUM | SPECIFIC TESTS/Color of Solution | USP36–NF31 | 3464 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample solution: Change 20 mg/mL of Esomeprazole Magnesium in methanol to: 20 mg/mL of Esomeprazole Magnesium in methanol, filtered |
EGG PHOSPHOLIPIDS | ASSAY/Content of Phospholipids | USP36–NF31 | 2000 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Solution A: Change acetic acid to: glacial acetic acid AND Line 2 of Solution B: Change acetic acid to: glacial acetic acid |
OCTOCRYLENE | Identification, Ultraviolet Absorption <197U> | USP36–NF31 | 4557 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 4: Change Absorptivities, calculated on the as-is basis, to: Absorptivity at 303 nm, calculated on the as-is basis, |
LAUROYL POLYOXYLGLYCERIDES | IMPURITIES/Limit of Free Glycerol | USP36–NF31 | 2064 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Mode in Titrimetric system: Change Direct titration to: Residual titration AND Line 10 of Analysis: Change (VS − VB) to: (VB − VS) AND Line 11 of Analysis:… Read More |
RIMEXOLONE OPHTHALMIC SUSPENSION | Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 5053 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |